骨巨细胞瘤的地舒单抗药物治疗

Denosumab in the treatment of giant cell tumor of bone

骨巨细胞瘤(giant cell tumor of bone,GCTB)是一种交界性的原发骨肿瘤,在临床上,具有局部侵袭性,可出现局部复发和远处转移[1-2]。GCTB的发病率在不同国家和地区并不相同,在欧美,GCTB的发病率为每年1.03~1.17/百万人[3],我国的发病率明显高于欧美人群,约为1.49~2.57/百万人[4]。

As an intermediate tumor,giant cell tumor of bone (GCT) has always been a challenge in treatment.However,the treatment of GCT that is unresectable or may lead to severe dysfunction changes a lot along with the approval of Denosumab in China.In this paper,we introduce the GCT staging,concept and content of being resectable / unresectable,and pathogenesis based on RANK-RANKL activation pathway to explain the mechanism of Denosumab.Drug administration of resectable and unresectable GCT is clarified based on the clinical trial data of Denosumab.Complete tumor removal is emphasized as a key to reduce the risk of postoperative recurrence.In addition,adverse effects including jaw osteonecrosis and hypocalcemia are described.